10QSB
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-QSB
(Mark
One)
x |
QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the
quarterly period ended March
31, 2008
OR
o |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
For
the
transition period from __________ to __________
Commission
File Number 0-2000
ENTRX
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
|
95-2368719
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
No.)
|
|
|
|
|
|
|
800
Nicollet Mall, Suite 2690, Minneapolis, MN
|
55402
|
(Address
of Principal Executive Office)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (612)
333-0614
Check
whether the Registrant (1) has filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months
(or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90
days. Yes x No
o
Indicate
by check mark whether the Registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes o
No
x
As
of May
5, 2008, the registrant had 7,656,147 shares outstanding of its Common Stock,
$.10 par value.
Transitional
Small Business Disclosure Format (check one): Yes o No
x
ENTRX
CORPORATION AND SUBSIDIARIES
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
2
|
|
|
|
|
|
3
|
|
|
|
|
|
4
|
|
|
|
|
|
9
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
15
|
|
|
|
|
|
18
|
|
|
|
|
|
19
|
|
|
|
|
20
|
References
to “we”, “us”, “our”, “the registrant” and “the Company” in this quarterly
report on Form 10-QSB shall mean or refer to Entrx Corporation and its
consolidated subsidiary, Metalclad Insulation Corporation, unless the context
in
which those words are used would indicate a different
meaning.
FINANCIAL
INFORMATION
ENTRX
CORPORATION AND SUBSIDIARIES
|
|
March
31,
2008
|
|
December
31,
2007
|
|
|
|
(unaudited)
|
|
(audited)
|
|
ASSETS
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
2,631,821
|
|
$
|
1,444,883
|
|
Available-for-sale
securities
|
|
|
597,075
|
|
|
559,436
|
|
Accounts
receivable, less allowance for doubtful accounts of $80,000 as of
March
31, 2008 and December 31, 2007
|
|
|
4,414,826
|
|
|
5,466,889
|
|
Costs
and estimated earnings in excess of billings on uncompleted
contracts
|
|
|
914,345
|
|
|
631,625
|
|
Inventories
|
|
|
256,466
|
|
|
107,118
|
|
Prepaid
expenses and other current assets
|
|
|
113,780
|
|
|
273,156
|
|
Insurance
claims receivable
|
|
|
6,500,000
|
|
|
7,000,000
|
|
Shareholder
note receivable, net of allowance of $1,364,000 and $1,356,000 as
of March
31, 2008 and December 31, 2007, respectively
|
|
|
17,500
|
|
|
25,000
|
|
Other
receivables
|
|
|
181,713
|
|
|
180,015
|
|
Total
current assets
|
|
|
15,627,526
|
|
|
15,688,122
|
|
|
|
|
|
|
|
|
|
Property,
plant and equipment, net
|
|
|
381,070
|
|
|
366,954
|
|
Investments
in unconsolidated affiliates
|
|
|
450,000
|
|
|
450,000
|
|
Insurance
claims receivable
|
|
|
27,750,000
|
|
|
29,000,000
|
|
Other
assets
|
|
|
193,540
|
|
|
193,540
|
|
|
|
$
|
44,402,136
|
|
$
|
45,698,616
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Current
portion of long-term debt
|
|
$
|
119,554
|
|
$
|
113,000
|
|
Accounts
payable
|
|
|
1,217,475
|
|
|
1,251,423
|
|
Accrued
expenses
|
|
|
1,746,400
|
|
|
1,859,048
|
|
Reserve
for asbestos liability claims
|
|
|
6,500,000
|
|
|
7,000,000
|
|
Billings
in excess of costs and estimated earnings on uncompleted
contracts
|
|
|
111,524
|
|
|
62,394
|
|
Total
current liabilities
|
|
|
9,694,953
|
|
|
10,285,865
|
|
|
|
|
|
|
|
|
|
Long-term
debt, less current portion
|
|
|
135,471
|
|
|
132,470
|
|
Reserve
for asbestos liability claims
|
|
|
27,750,000
|
|
|
29,000,000
|
|
Total
liabilities
|
|
|
37,580,424
|
|
|
39,418,335
|
|
|
|
|
|
|
|
|
|
Commitments
and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’
equity:
|
|
|
|
|
|
|
|
Preferred
stock, par value $1; 5,000,000 shares authorized; none
issued
|
|
|
—
|
|
|
—
|
|
Common
stock, par value $0.10; 80,000,000 shares authorized; 7,656,147 issued
and
outstanding at March 31, 2008 and 7,616,147 issued and outstanding
at
December 31, 2007
|
|
|
811,095
|
|
|
807,095
|
|
Additional
paid-in capital
|
|
|
69,831,881
|
|
|
69,821,881
|
|
Accumulated
deficit
|
|
|
(63,815,547
|
)
|
|
(64,132,186
|
)
|
Accumulated
other comprehensive loss
|
|
|
(5,717
|
)
|
|
(216,509
|
)
|
Total
shareholders’ equity
|
|
|
6,821,712
|
|
|
6,280,281
|
|
|
|
$
|
44,402,136
|
|
$
|
45,698,616
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See
Notes
to Consolidated Financial Statements
ENTRX
CORPORATION AND SUBSIDIARIES
(Unaudited)
|
|
Three
Months Ended March 31,
|
|
|
|
2008
|
|
2007
|
|
|
|
|
|
|
|
Contract
revenues
|
|
$
|
8,556,750
|
|
$
|
4,470,634
|
|
|
|
|
|
|
|
|
|
Contract
costs and expenses
|
|
|
7,130,964
|
|
|
3,817,469
|
|
|
|
|
|
|
|
|
|
Gross
margin
|
|
|
1,425,786
|
|
|
653,165
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
Selling,
general and administrative
|
|
|
948,502
|
|
|
699,294
|
|
Change
in allowance on shareholder note receivable
|
|
|
7,500
|
|
|
(28,750
|
)
|
Gain
on disposal of property, plant and equipment
|
|
|
(11,850
|
)
|
|
(2,800
|
)
|
Total
operating expenses
|
|
|
944,152
|
|
|
667,744
|
|
|
|
|
|
|
|
|
|
Operating
income (loss)
|
|
|
481,634
|
|
|
(14,579
|
)
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
10,527
|
|
|
14,528
|
|
Interest
expense
|
|
|
(2,369
|
)
|
|
(5,139
|
)
|
Impairment
charge on available-for-sale securities
|
|
|
(173,153
|
)
|
|
—
|
|
|
|
|
|
|
|
|
|
Net
income (loss)
|
|
|
316,639
|
|
|
(5,190
|
)
|
|
|
|
|
|
|
|
|
Other
comprehensive income (loss)
|
|
|
|
|
|
|
|
Unrealized
gains (losses) on available-for-sale securities
|
|
|
(5,717
|
)
|
|
56,617
|
|
|
|
|
|
|
|
|
|
Comprehensive
income
|
|
$
|
310,922
|
|
$
|
51,427
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares — basic and diluted
|
|
|
7,644,279
|
|
|
8,030,536
|
|
|
|
|
|
|
|
|
|
Net
income per share of common stock — basic and diluted
|
|
$
|
0.04
|
|
$
|
(0.00
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See
Notes
to Consolidated Financial Statements
ENTRX
CORPORATION AND SUBSIDIARIES
|
|
Three
Months Ended March 31,
|
|
|
|
2008
|
|
2007
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
Cash
flows from operating activities:
|
|
|
|
|
|
Net
income (loss)
|
|
$
|
316,639
|
|
$
|
(5,190
|
)
|
Adjustments
to reconcile net income (loss) to net cash provided by operating
activities:
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
51,165
|
|
|
47,098
|
|
Gain
on disposal of property, plant and equipment
|
|
|
(11,850
|
)
|
|
(2,800
|
)
|
Impairment
charge on investment
|
|
|
173,153
|
|
|
—
|
|
Common
stock issued for services
|
|
|
14,000
|
|
|
18,400
|
|
Allowance
on shareholder note receivable
|
|
|
7,500
|
|
|
(28,750
|
)
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
1,052,063
|
|
|
499,070
|
|
Costs
and estimated earnings in excess of billings on uncompleted
contracts
|
|
|
(282,720
|
)
|
|
38,707
|
|
Inventories
|
|
|
(149,348
|
)
|
|
(78,002
|
)
|
Prepaid
expenses and other current assets
|
|
|
159,376
|
|
|
113,119
|
|
Other
receivables
|
|
|
(1,698
|
)
|
|
3,809
|
|
Accounts
payable and accrued expenses
|
|
|
(146,596
|
)
|
|
(299,532
|
)
|
Billings
in excess of costs and estimated earnings on uncompleted
contracts
|
|
|
49,130
|
|
|
(58,525
|
)
|
Net
cash provided by operating activities
|
|
|
1,230,814
|
|
|
247,404
|
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities:
|
|
|
|
|
|
|
|
Capital
expenditures
|
|
|
(5,254
|
)
|
|
(56,491
|
)
|
Proceeds
from sale of property, plant and equipment, net of
expenses
|
|
|
—
|
|
|
2,800
|
|
Net
cash used in investing activities
|
|
|
(5,254
|
)
|
|
(53,691
|
)
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
Proceeds
from long-term debt
|
|
|
—
|
|
|
54,399
|
|
Payments
on long-term debt
|
|
|
(38,622
|
)
|
|
(31,135
|
)
|
Net
cash (used in) provided by financing activities
|
|
|
(38,622
|
)
|
|
23,264
|
|
|
|
|
|
|
|
|
|
Increase
in cash and cash equivalents
|
|
|
1,186,938
|
|
|
216,977
|
|
Cash
and cash equivalents at beginning of period
|
|
|
1,444,883
|
|
|
1,607,580
|
|
Cash
and cash equivalents at end of period
|
|
$
|
2,631,821
|
|
$
|
1,824,557
|
|
|
|
|
|
|
|
|
|
Non-cash
investing and financing activities:
|
|
|
|
|
|
|
|
Acquisition
of property, plant and equipment
|
|
|
|
|
|
|
|
in
exchange for notes payable
|
|
$
|
59,239
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See
Notes
to Consolidated Financial Statements
ENTRX
CORPORATION AND SUBSIDIARIES
For
the Three Months Ended March 31, 2008 and 2007
(Unaudited)
1. The
accompanying unaudited consolidated financial statements of Entrx Corporation
and its subsidiaries (the "Company") have been prepared in accordance with
accounting principles generally accepted in the United States of America for
interim financial information and the instructions to Form 10-QSB. Accordingly,
they do not include all of the information and footnotes required by accounting
principles generally accepted in the United States of America. In the opinion
of
management all adjustments, consisting of normal recurring items, necessary
for
a fair presentation have been included. Operating results for the three months
ended March 31, 2008 are not necessarily indicative of the results that may
be
expected for the year ending December 31, 2008. These consolidated financial
statements should be read in conjunction with the consolidated financial
statements and footnotes thereto included in the Company's Annual Report on
Form
10-KSB for the year ended December 31, 2007.
2. The
income per share amounts for the three months ended March 31, 2008 and 2007,
were computed by dividing the net income by the weighted average shares
outstanding during the applicable period. Dilutive common equivalent shares
have
not been included in the computation of diluted income per share because their
inclusion would be antidilutive.
All
stock
options and warrants were anti-dilutive for the three months ended March 31,
2008 and 2007 because their respective exercise prices were greater than the
average market price of the common stock.
3. Investments
held by the Company are classified as available-for-sale securities.
Available-for-sale securities are reported at fair value with all unrealized
gains or losses included in other comprehensive income (loss). The fair value
of
the securities was determined by quoted market prices of the underlying
security. For purposes of determining gross realized gains (losses), the cost
of
available-for-sale securities is based on specific identification.
|
|
Aggregate
fair
value
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Cost
|
|
Available
for sale securities - March 31, 2008
|
|
$
|
597,075
|
|
$
|
—
|
|
$
|
(5,717
|
)
|
$
|
602,792
|
|
Available
for sale securities - December 31, 2007
|
|
$
|
559,436
|
|
$
|
—
|
|
$
|
(216,509
|
)
|
$
|
775,945
|
|
The
Company's net unrealized holding gain (loss) was $(5,717) and $56,617 for the
three months ended March 31, 2008 and 2007, respectively.
On
an
ongoing basis, the Company evaluates its investments in available-for-sale
securities to determine if a decline in fair value is other-than-temporary.
When
a decline in fair value is determined to be other-than-temporary, an impairment
charge is recorded and a new cost basis in the investment is established.
Considering
the severity and duration of the decline in fair value and the financial
condition and near-term prospects of our investments, we recognized an other
than temporary impairment charge in the amount of $173,153 during the three
months ended March 31, 2008 on one of our investments.
The
following table shows the gross unrealized losses and fair value of the
Company's investments with unrealized losses that are not deemed to be
other-than-temporarily impaired, aggregated by investment category and length
of
time that individual securities have been in a continuous unrealized loss
position, at March 31, 2008.
|
|
Less
than 12 Months
|
|
12
Months or Greater
|
|
Total
|
|
Description
of Securities
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Fair
Value
|
|
Unrealized
Losses
|
|
Marketable
equity securities
|
|
$
|
597,075
|
|
$
|
(5,717
|
)
|
$
|
—
|
|
$
|
—
|
|
$
|
597,075
|
|
$
|
(5,717
|
)
|
Total
|
|
$
|
597,075
|
|
$
|
(5,717
|
)
|
$
|
—
|
|
$
|
—
|
|
$
|
597,075
|
|
$
|
(5,717
|
)
|
The
Company also has a minority investment in a company. This investment is included
in investments in unconsolidated affiliates on the Consolidated Balance Sheets
and is carried at cost unless the fair value of the investment below the cost
basis is judged to be other-than-temporary. The Company monitors this investment
for impairment on an ongoing basis.
4. Inventories,
which consist principally of insulation products and related materials, are
stated at the lower of cost (determined on the first-in, first-out method)
or
market.
5. Blake
Capital Partners, LLC was current in the payment of interest on the shareholder
note receivable through the payment due March 1, 2006. The payment due September
1, 2006, however, was not made, and we have been informed by Mr. Mills, the
principal of Blake Capital Partners and guarantor on the note, that no payment
can be expected in the foreseeable future. For the year ended December 31,
2006,
we increased our reserve against the note receivable from Blake Capital
Partners, LLC (“Blake”) by $1,083,885 as a result of the non-payment of
interest, bringing the net of the note receivable less the reserve down to
$210,000, the approximate value of the collateral securing the note. In April
2007, the Company canceled 500,000 shares of the Company’s common stock that
were pledged as collateral on the note and applied the $115,000 value of the
stock against the outstanding note balance. The note was not repaid on the
October 31, 2007 due date. As of December 31, 2007 the Company adjusted the
net
book value of the note to $25,000, the approximate value of the collateral
securing the note. The Company is also exploring its opportunities to obtain
proceeds from the sale of the 250,000 shares of VioQuest Pharmaceuticals, Inc.
common stock pledged as collateral on the note. During the three months ended
March 31, 2008, the Company recorded an additional provision to adjust the
carrying value of the note receivable to the approximate value of the collateral
securing the note at March 31, 2008.
6. Accrued
expenses consist of the following:
|
|
March
31,
2008
|
|
December
31,
2007
|
|
Wages,
bonuses and payroll taxes
|
|
$
|
610,579
|
|
$
|
677,096
|
|
Union
dues
|
|
|
435,840
|
|
|
462,483
|
|
Accounting
and legal fees
|
|
|
48,500
|
|
|
42,000
|
|
Insurance
|
|
|
59,510
|
|
|
61,147
|
|
Insurance
settlement reserve
|
|
|
375,000
|
|
|
375,000
|
|
Inventory
purchases
|
|
|
24,129
|
|
|
44,871
|
|
Taxes
|
|
|
33,143
|
|
|
—
|
|
Other
|
|
|
159,699
|
|
|
196,451
|
|
|
|
$
|
1,746,400
|
|
$
|
1,859,048
|
|
7. As
more
fully described in our Annual Report on Form 10-KSB for the year ended December
31, 2007, the Company has granted stock options over the years to employees
and
directors under various stockholder approved stock option plans. At March 31,
2008, 2,109,400 stock options are outstanding. No stock options were granted
during the first three months of 2008 or 2007. Stock options expiring during
the
first three months of 2008 and 2007 were 82,230 and 580, respectively. Stock
warrants expiring in the first three months of 2008 were 50,000.
8. Sales
for
the three months ended March 31, 2008 to i) Jacobs Field Services North America,
Inc. were approximately $1,190,000, representing 13.9% of total revenues ii)
ARB, Inc. were approximately $1,955,000, representing 22.8% of total revenues
and iii) BP Carson Business Unit were approximately $2,185,000, representing
25.5% of total revenues. Sales for the three months ended March 31, 2007 to
i)
Jacobs Field Services North America, Inc. were approximately $697,000,
representing 15.6% of total revenues ii) NRG Energy, Inc. were approximately
$526,000, representing 11.8% of total revenues and iii) Matrix Service, Inc.
were approximately $1,345,000, representing 30.1% of total revenues. Accounts
receivable from ARB, Inc. was approximately $1,271,000 and from Jacobs Field
Services North America, Inc. was approximately $881,000, representing 28.3%
and
19.6% of total accounts receivable, respectively, as of March 31, 2008. Accounts
receivable from Southern California Edison Company was approximately $694,000,
from ARB, Inc. was $1,516,000 and from Jacobs Field Services North America,
Inc.
was approximately $992,000 at December 31, 2007. Since many of the projects
we
under take are relatively large, it is normal that various customers will
represent a significant portion of our sales and/or accounts receivable in
a
given period. It is also the nature of the Company’s business that a significant
customer in one year may not be a significant customer in a succeeding
year.
9. In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. SFAS
No.
157 defines fair value, establishes a framework for measuring fair value in
generally accepted accounting principles and expands disclosures about fair
value measurements. SFAS No. 157 applies under other accounting pronouncements
that require or permit fair value
measurements,
the FASB having previously concluded in those accounting pronouncements that
fair value is the relevant measurement attribute. SFAS No. 157 became effective
for most fair value measurements, other than leases and certain nonfinancial
assets and liabilities, beginning January 1, 2008. SFAS No. 157 establishes
a
three-level fair value hierarchy and requires fair value disclosures based
on
this hierarchy. The method used to measure the fair value of our available
for
sale securities and collateral held on a shareholder note receivable is quoted
prices in active markets for identical assets or liabilities (Level
1).
In
February 2007, the FASB issued Statement of Financial Accounting Standards
No.
159 (SFAS 159), "The Fair Value Option for Financial Assets and Financial
Liabilities". SFAS 159 permits entities to choose to measure certain financial
instruments and certain other items at fair value. Unrealized gains and losses
on items for which the fair value option has been elected are reported in
earnings. SFAS 159 is effective for fiscal years beginning after November 15,
2007. The Company adopted SFAS 159 on January 1, 2008 and did not elect to
apply
SFAS 159 to its financial assets and liabilities. Therefore, the adoption of
SFAS 159 had no impact on the Company's financial position and results of
operations.
In
December 2007, the FASB issued SFAS No. 141(R), Business Combinations. SFAS
141(R) requires the acquiring entity in a business combination to record all
assets acquired and liabilities assumed at their respective acquisition-date
fair values and changes other practices under SFAS No. 141, Business
Combinations, some of which could have a material impact on how an entity
accounts for its business combinations. SFAS 141(R) also requires additional
disclosure of information surrounding a business combination. SFAS 141(R) is
effective for fiscal years beginning after December 15, 2008, and is to be
applied prospectively to business combinations for which the acquisition date
is
on or after December 15, 2008. The provisions of SFAS 141(R) will only impact
the Company if it is party to a business combination after the pronouncement
has
been adopted.
In
December 2007, the FASB issued SFAS No. 160, Noncontrolling Interest in
Consolidated Financial Statements - an amendment of ARB No. 51. SFAS 160
requires entities to report non-controlling minority interests in subsidiaries
as equity in consolidated financial statements. SFAS 160 is effective for fiscal
years beginning on or after December 15, 2008. The Company does not believe
that
SFAS 160 will have any impact on its financial position or results of operations
since none of its subsidiaries are owned by minority interests.
In
March
2008, the FASB issued Statement of Financial Accounting Standards No. 161,
Disclosures
about Derivative Instruments and Hedging Activities, an Amendment of FASB
Statement No. 133.
SFAS
No. 161 amends and expands upon the disclosure requirements for derivative
financial instruments and for hedging activities required under FASB Statement
No. 133 to provide users of financial statements with an enhanced understanding
of how and why an entity uses derivative financial instruments, how derivative
financial instruments are accounted for under Statement 133 and it related
interpretations, and how derivative financial instruments affect an entity’s
financial position, financial performance, and results of operations. SFAS
No.
161 is effective for financial statement and interim periods beginning after
November 15, 2008. The Company does not currently hold any derivative financial
instruments, and therefore, the Company does not expect that the adoption of
SFAS No. 161 will have a material affect on its financial statements and
disclosures.
10. In
October 1999, we completed the sale of our operating businesses and development
project located in Aguascalientes, Mexico. That sale specifically excluded
those
Mexican assets involved in the Company’s NAFTA claim which was settled in 2001.
Under the terms of the sale we received an initial cash payment of $125,000
and
recorded a receivable for $779,000, which has been fully reserved. Entrx
continues to pursue claims in Mexico against Javier Guerra Cisneros and
Promotora Industrial Galeana, S.A. de C.V. related to this sale.
11. The
number of asbestos-related cases which have been initiated naming us (primarily
our subsidiary, Metalclad Insulation Corporation) as a defendant decreased
from
232 in 2006 to 163 in 2007. At December 31, 2006 and 2007, there were,
respectively, approximately 404 and 222 cases pending. These claims are
currently defended and covered by insurance. There were 40 new claims made
in
the first three months of 2008, compared to 37 in the first three months of
2007. There were 218 cases pending at March 31, 2008. These claims are currently
defended and covered by insurance.
The
number of asbestos-related claims made against the Company has reflected a
general downward trend. We believe that it is probable that this general trend
will continue, although such continuance cannot be assured. From
2001
and through 2006, the annual average indemnity paid on over 2,550 resolved
cases
has fluctuated between a low of $14,504 in 2006 and a high of $26,520 in 2001,
with an overall average over that period of approximately $19,131. Since 2001,
there has been no discernible upward or downward trend in indemnity payments.
The indemnity paid on the 44 cases resolved in the first quarter ended March
31,
2008 averaged $107,308, as a result of one case in which the plaintiff received
a jury award of $1,659,000 and three other cases settling for approximately
$1,000,000 each. As a further result, we estimate that the
average
indemnity
paid on all claims resolved in 2008 will increase to over $30,000. We have
chosen not to recalculate the average indemnity based upon the 2008
first-quarter results, as we do not anticipate a similar spike in any quarter
during the rest of this year. Accordingly, we intend to continue to use the
$19,131 average indemnity payment in estimating our aggregate asbestos-related
personally injury liability unless we are prompted to alter this number by
the
next quarter’s results, or until we are able to take into consideration the
results of resolved cases during the remainder of 2008.
We
believe that the sympathies of juries, the aggressiveness of the plaintiffs’ bar
and the declining base of potential defendants as the result of business
failures, have tended to increase payments on resolved cases. This tendency,
we
believe, has been mitigated by the declining pool of claimants resulting from
death, and the likelihood that the most meritorious claims have been ferreted
out by plaintiffs’ attorneys and that the newer cases being brought are not as
meritorious nor do they have as high a potential for damages as do cases which
were brought earlier. We have no reason to believe, therefore, that the average
future indemnity payments will increase materially in the future.
In
addition, direct defense costs per resolved claim have been approximately
$13,500 per claim.
Based
on
the general trend of reducing asbestos-related injury claims made against the
Company we projected in our Form 10-KSB filed with the Securities and Exchange
Commission for the year ended December 31, 2006 that there would be 924
asbestos-related injury claims made against the Company after December 31,
2006.
The 924, in addition to the 404 claims existing as of December 31, 2006, totaled
1,328 current and future claims. Multiplying the average indemnity per resolved
claim of $19,131, times 1,328, we projected the probable future indemnity to
be
paid on those claims after December 31, 2006 to be equal to approximately $25
million. In addition, multiplying an estimated cost of defense per resolved
claim of approximately $13,500 times 1,328, we projected the probable future
defense costs to equal approximately $18 million. Accordingly, our total
estimated future asbestos-related liability at December 31, 2006 was $43
million.
As
of
December 31, 2006, we projected that approximately 186 new asbestos-related
claims would be commenced, and approximately 237 cases would be resolved, in
2007, resulting in an estimated 353 cases pending at December 31, 2007. Although
the actual number of claims made in 2007 was 163 and the number of cases pending
as of December 31, 2007 was 222, slightly less than we anticipated, we did
not
believe the differences were significant enough to re-evaluate our estimate.
In
addition, our future defense costs and average indemnity per resolved case
could
be greater than projected, and such increase could partially offset any lower
projection of liability which would result from such re-evaluation. Since we
projected that an aggregate of 738 new cases would be commenced after December
31, 2007, and that 148 of these cases would be commenced in 2008, we estimated
that an aggregate of 590 new cases would be commenced after December 31, 2008.
Accordingly, we have projected the cases pending and projected to be commenced
in the future at December 31, 2008, would be 897 cases. Multiplying 897 claims
times the approximate average indemnity paid and defense costs incurred per
resolved claim of $32,600, we estimated our liability for current and future
asbestos-related claims at December 31, 2008 to be approximately $29,000,000.
This amounts to a $7,000,000 reduction from the $36,000,000 liability we
estimated as of December 31, 2007, or a $1,750,000 reduction per quarter in
2008.
We
have
determined that it is probable that we have sufficient insurance to provide
coverage for both current and future projected asbestos-related injury claims.
This determination assumes that the current trend of reducing asbestos-related
injury claims will continue and that the average indemnity and direct legal
costs of each resolved claim will not materially increase. The determination
also assumes that the insurance companies live up to what we believe is their
obligation to continue to cover our exposure with regards to these claims.
Several affiliated insurance companies have brought a declaratory relief action
against our subsidiary, Metalclad, as well as a number of other insurers, to
resolve certain coverage issues.
We
intend
to re-evaluate our estimate of future liability for asbestos claims at the
end
of each fiscal year, or whenever actual results are materially different from
our estimates, integrating our actual experience in that fiscal year with that
of prior fiscal years. We estimate that the effects of economic inflation on
either the average indemnity payment or the projected direct legal expenses
will
be approximately equal to a discount rate applied to our future liability based
upon the time value of money. It is probable that we have adequate insurance
to
cover current and future asbestos-related claims, although such coverage cannot
be assured.
Although
defense costs are included in our insurance coverage, we expended $65,000 during
the three months ended March 31, 2008 and $107,000 during the three months
ended
March 31, 2007 to administer the asbestos claims and defend the ACE Lawsuit
discussed below. These amounts were primarily fees paid to attorneys to monitor
the activities of the insurers, and their selected defense counsel, and to
look
after our rights under the various insurance policies.
There
are
numerous insurance carriers which have issued a number of policies to us over
a
period extending from approximately 1967 through approximately 1985 that still
provide coverage for asbestos-related injury claims. After approximately 1985
the policies were issued with provisions which purport to exclude coverage
for
asbestos related claims. The terms of our insurance policies are complex, and
coverage for many types of claims is limited as to the nature of the claim
and
the amount of coverage available. It is clear, however, under California law,
where the substantial majority of the asbestos-related injury claims are
litigated, that all of those policies cover any asbestos-related injury
occurring during the 1967 through 1985 period when these policies were in
force.
We
have
engaged legal counsel to review all of our known insurance policies, and to
provide us with the amount of coverage which such counsel believes to be
probable under those policies for current and future asbestos-related injury
claims against us. Such legal counsel has provided us with its opinion of the
minimum probable insurance coverage available to satisfy asbestos-related injury
claims, which significantly exceeds our estimated $36 million future liability
for such claims as of December 31, 2007. Accordingly, we have included
$34,250,000 and $36,000,000 of such insurance coverage receivable as an asset
on
our March 31, 2008 and December 31, 2007 balance sheets,
respectively.
On
February 23, 2005 ACE Property & Casualty Company ("ACE"), Central National
Insurance Company of Omaha ("Central National") and Industrial Underwriters
Insurance Company ("Industrial"), which are all related entities, filed a
declaratory relief lawsuit (“the ACE Lawsuit”) against Metalclad Insulation
Corporation (“Metalclad”) and a number of Metalclad's other liability insurers,
in the Superior Court of the State of California, County of Los Angeles. ACE,
Central National and Industrial issued umbrella and excess policies to
Metalclad, which has sought and obtained from the plaintiffs both defense and
indemnity under these policies for the asbestos lawsuits brought against
Metalclad during the last four to five years. The ACE Lawsuit seeks declarations
regarding a variety of coverage issues, but is centrally focused on issues
involving whether historical and currently pending asbestos lawsuits brought
against Metalclad are subject to either an "aggregate" limits of liability
or
separate "per occurrence" limits of liability. Whether any particular asbestos
lawsuit is properly classified as being subject to an aggregate limit of
liability depends upon whether or not the suit falls within the "products"
or
"completed operations" hazards found in most of the liability policies issued
to
Metalclad. Resolution of these classification issues will determine if, as
ACE
and Central National allege, their policies are nearing exhaustion of their
aggregate limits and whether or not other Metalclad insurers who previously
asserted they no longer owed any coverage obligations to Metalclad because
of
the claimed exhaustion of their aggregate limits, in fact, owe Metalclad
additional coverage obligations. The ACE Lawsuit also seeks to determine the
effect of the settlement agreement between the Company and Allstate Insurance
Company on the insurance obligations of various other insurers of Metalclad,
and
the effect of the “asbestos exclusion” in the Allstate policy. The ACE Lawsuit
does not seek any monetary recovery from Metalclad. Nonetheless, we anticipate
that we will incur attorneys fees and other associated litigation costs in
defending the lawsuit and any counter claims made against us by any other
insurers, and in prosecuting any claims we may seek to have adjudicated
regarding our insurance coverage. In addition, the ACE Lawsuit may result in
our
incurring costs in connection with obligations we may have to indemnify Allstate
under the settlement agreement. Allstate, in a cross-complaint filed against
Metalclad Insulation Corporation in October, 2005, asked the court to determine
the Company’s obligation to assume and pay for the defense of Allstate in the
ACE Lawsuit under the Company’s indemnification obligations in the settlement
agreement. The Company does not believe that it has any legal obligation to
assume or pay for such defense.
In
June
2004, Metalclad Insulation Corporation, our wholly owned subsidiary, and Entrx
Corporation, entered into a Settlement Agreement and Full Policy Release (the
“Agreement”) releasing Allstate Insurance Company from its policy obligations
for a broad range of claims arising from injury or damage which may have
occurred during the period March 15, 1980 to March 15, 1981, under an umbrella
liability policy (the “Policy”). The Policy provided limits of $5,000,000 in the
aggregate and per occurrence. Allstate claimed that liability under the Policy
had not attached, and that regardless of that fact, an exclusion in the Policy
barred coverage for virtually all claims of bodily injury from exposure to
asbestos, which is of primary concern to Metalclad Insulation Corporation.
Metalclad Insulation Corporation took the position that such asbestos coverage
existed. The parties to the Agreement reached a compromise, whereby Metalclad
Insulation Corporation received $2,500,000 in cash, and Metalclad Insulation
Corporation and Entrx Corporation agreed to indemnify and hold harmless the
insurer from all claims which could be alleged against the insurer respecting
the policy, limited to $2,500,000 in amount. Based on past experience related
to
asbestos insurance coverage, we believe that the Agreement we entered into
in
June 2004, will result in a probable loss contingency for future insurance
claims based on the indemnification provision in the Agreement. Although we
are
unable to estimate the exact amount of the loss, we believe at this time the
reasonable estimate of the loss will not be less than $375,000 or more than
$2,500,000 (the $2,500,000 represents the maximum loss we would have based
on
the indemnification provision in the Agreement). Based on the information
available to us, no amount in this range appears at this time to be a better
estimate than any other amount. The $375,000 estimated loss contingency noted
in
the above range represents 15% of the $2,500,000 we received and is based upon
our attorney’s informal and general inquiries to an insurance company of the
cost for us to purchase an insurance policy to cover the indemnification
provision we
entered
into. We recorded a reserve of $375,000 at the time we entered into the
Agreement and nothing has come to our attention that would require us to record
a different estimate at March 31, 2008. The ACE Lawsuit may result in our
incurring costs in connection with obligations we may have to indemnify Allstate
under the Settlement Agreement. Allstate, in a cross-complaint filed against
Metalclad Insulation Corporation in October, 2005, asked the court to determine
the Company’s obligation to assume and pay for the defense of Allstate in the
ACE Lawsuit under the Company’s indemnification obligations in the Settlement
Agreement. The Company is taking the position that it has no legal obligation
to
assume or pay for such defense.
12. Supplemental
disclosures of cash flow information:
Cash
paid
for interest was $2,369 and $5,139 for the three months ended March 31, 2008
and
2007, respectively.
All
statements, other than statements of historical fact, included in this Form
10-QSB, including without limitation the statements under “Management’s
Discussion and Analysis or Plan of Operation” and “Description of Business” are,
or may be deemed to be, “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties, and other factors which
may
cause the actual results, performance or achievements of Entrx Corporation
(the
“Company”) to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements contained
in this Form 10-QSB. Such potential risks and uncertainties include, without
limitation; the outcome of existing litigation; competitive pricing and other
pressures from other businesses in the Company’s markets; the accuracy of the
Company’s estimate of future liability for asbestos-related injury claims; the
adequacy of insurance, including the adequacy of insurance to cover current
and
future asbestos-related injury claims; the valuation of the Company’s
investments; collectibility of a loan due from an affiliate of, and guaranteed
by, a principal shareholder; economic conditions generally and in the Company’s
primary markets; availability of capital; the adequacy of the Company’s cash and
cash equivalents; the cost of labor; the accuracy of the Company’s cost analysis
for fixed price contracts; and other risk factors detailed herein and in other
of the Company’s filings with the Securities and Exchange Commission. The
forward-looking statements are made as of the date of this Form 10-QSB and
the
Company assumes no obligation to update the forward-looking statements or to
update the reasons actual results could differ from those projected in such
forward-looking statements. Therefore, readers are cautioned not to place undue
reliance on these forward-looking statements. You
can
identify these forward-looking statements by forward-looking words such as
“may,” “will,” “expect,” “anticipate,” “believe,” “intend,” “estimate,”
“continue,” and similar words.
General.
The
Company provides insulation and asbestos abatement services, primarily on the
West Coast. Through our wholly-owned subsidiary Metalclad Insulation
Corporation, we provide these services to a wide range of industrial, commercial
and public agency clients. Insulation services include the installation of
high-
and low-temperature insulation on pipe, ducts, furnaces, boilers, and other
types of industrial equipment and commercial applications. Asbestos abatement
services include removal and disposal of asbestos-containing products in similar
applications. We fabricate specialty items for the insulation industry, and
sell
insulation material and accessories incidental to our services business to
our
customers as well as to other contractors. A diverse list of clientele includes
refineries, utilities, chemical/petrochemical plants, manufacturing facilities,
commercial properties, office buildings and various governmental
facilities.
Results
of Operations: Three Months Ended March 31, 2008 and
2007
Revenue
Revenue
for the three months ended March 31, 2008 was $8,557,000, an increase of 91.4%
as compared to $4,471,000 for the three months ended March 31, 2007. Revenues
increased during the three months ended March 31, 2008 as compared with the
three months ended March 31, 2007 primarily as result of the Company obtaining
new maintenance contracts, and hiring additional project managers which has
allowed the Company to bid on more projects in 2008 and ultimately increased
the
number of jobs in which we were the winning bidder.
Cost
of Revenue and Gross Margin
Cost
of
revenue was $7,131,000 for the three months ended March 31, 2008, as compared
to
$3,817,000 for the three months ended March 31, 2007. The gross margin
percentage was approximately 16.7% for the three months ended March 31, 2008
as
compared to 14.6% for the three months ended March 31, 2007. The increase in
the
gross margin percentage during the three months ended March 31, 2008 as compared
with the three months ended March 31, 2007 is primarily the result of lower
rates on our workers compensation insurance and the Company’s expansion into
commercial insulation and abatement which generally allows for higher gross
margin than industrial insulation and abatement.
Selling,
General and Administrative
Selling,
general and administrative expenses for the three months ended March 31, 2008
were $949,000 as compared to $699,000 for the comparable period ended March
31,
2007, an increase of 35.6%. The increase for the three months ended March 31,
2008 as compared to the three months ended March 31, 2007 was primarily due
to
increases in payroll, the accrual for bonuses, taxes and consulting expenses
primarily related to complying with section 404 of the Sarbanes-Oxley Act.
The
increase in payroll expense was primarily due to an increase in the number
of
project managers at the Company which allows the Company to bid on more
projects. For the three months ended March 31, 2008, the overall increase in
selling, general and administrative costs was partially offset by a decrease
in
legal expenses.
Change
in Allowance on Shareholder Note Receivable
Blake
Capital Partners, LLC was current in the payment of interest on the shareholder
note receivable through the payment due March 1, 2006. The payment due September
1, 2006, however, was not made, and we have been informed by Mr. Mills, the
principal of Blake Capital Partners and guarantor on the note, that no payment
can be expected in the foreseeable future. For the year ended December 31,
2006,
we increased our reserve against the note receivable from Blake Capital
Partners, LLC (“Blake”) by $1,083,885 as a result of the non-payment of
interest, bringing the net of the note receivable less the reserve down to
$210,000, the approximate value of the collateral securing the note. In April
2007, the Company canceled 500,000 shares of the Company’s common stock that
were pledged as collateral on the note and applied the $115,000 value of the
stock against the outstanding note balance. The note was not repaid on the
October 31, 2007 due date. As of December 31, 2007 the Company adjusted the
net
book value of the note to $25,000, the approximate value of the collateral
securing the note. The Company is exploring its opportunities to obtain proceeds
from the sale of the 250,000 shares of VioQuest Pharmaceuticals, Inc. common
stock pledged as collateral on the note. As such, the Company adjusted the
carrying value of the note receivable to the approximate value of the collateral
securing the note at March 31, 2008. The Company increased the allowance on
the
shareholder note receivable $8,000 for the three months ended March 31, 2008
and
decreased the reserve $29,000 for the three months ended March 31,
2007.
Gain
on Disposal of Property, Plant and Equipment
Gain
on
the disposal of property plant and equipment was $12,000 and $3,000 for the
three months ended March 31, 2008 and 2007, respectively.
Interest
Income and Expense
Interest
income for the three months ended March 31, 2008 was $11,000 as compared to
interest income of $15,000 for the three months ended March 31, 2007. During
the
three months ended March 31, 2008 and 2007, the Company did not record any
interest income on the note receivable from Blake Capital Partners, LLC.
Interest expense for the three months ended March 31, 2008 was $2,000 as
compared to interest expense of $5,000 for the three months ended March 31,
2007.
Net
Income
We
had
net income of $317,000 for the three months ended March 31, 2008 as compared
to
a net loss of $5,000 for the three months ended March 31, 2007.
Liquidity
and Capital Resources
As
of
March 31, 2008, we had $2,632,000 in cash and cash equivalents and $597,000
in
available-for-sale securities. The Company had working capital of $5,933,000
as
of March 31, 2008. We own 190,566 shares of the common stock of
VioQuest
Pharmaceuticals, Inc., the common stock of which is publicly traded on the
NASD
Bulletin Board under the symbol “VQPH”. Of the 190,566 shares, 75,000 shares are
subject to options exercisable by one current and two former members of our
Board of Directors at $1.25 per share. We also own 39,415 shares of Clearwire
Corporation’s common stock (NASDAQ: CLWR).
In
an
effort to increase shareholder value and to diversify from our insulation
services business, we have made an equity investment in Catalytic Solutions,
Inc., that is not in the insulation services business and which we believed
had
the ability to provide acceptable return on our investment. We currently have
an
investment in Catalytic Solutions, Inc. which we value at $450,000. This company
is in the early stages of its business development. Our investment represents
less than 5% ownership and represent approximately 1.0% of the Company’s total
assets at March 31, 2008 and December 31, 2007. Catalytic Solutions, Inc.
manufactures and delivers proprietary technology that improves the performance
and reduces the cost of catalytic converters. Catalytic Solutions, Inc. is
traded on the AIM market in London, England.
Blake
Capital Partners, LLC was current in the payment of interest on the shareholder
note receivable through the payment due March 1, 2006. The payment due September
1, 2006, however, was not made, and we have been informed by Mr. Mills, the
principal of Blake Capital Partners and guarantor on the note, that no payment
can be expected in the foreseeable future. For the year ended December 31,
2006,
we increased our reserve against the note receivable from Blake Capital
Partners, LLC (“Blake”) by $1,083,885 as a result of the non-payment of
interest, bringing the net of the note receivable less the reserve down to
$210,000, the approximate value of the collateral securing the note. In April
2007, the Company canceled 500,000 shares of the Company’s common stock that
were pledged as collateral on the note and applied the $115,000 value of the
stock against the outstanding note balance. The note was not repaid on the
October 31, 2007 due date. As of December 31, 2007 the Company adjusted the
net
book value of the note to $25,000, the approximate value of the collateral
securing the note. The Company is exploring its opportunities to obtain proceeds
from the sale of the 250,000 shares of VioQuest Pharmaceuticals, Inc. common
stock pledged as collateral on the note. As such, the Company adjusted the
carrying value of the note receivable to the approximate value of the collateral
securing the note at March 31, 2008. The Company increased the allowance on
the
shareholder note receivable $8,000 for the three months ended March 31, 2008
and
decreased the reserve $29,000 for the three months ended March 31,
2007.
Cash
provided by operations was $1,231,000 for the three months ended March 31,
2008
compared with cash provided by operations of $247,000 for the three months
ended
March 31, 2007. For the three months ended March 31, 2008 the positive cash
flow
from operations was primarily the result of our $317,000 of net income and
a
decrease in accounts receivable of $1,052,000. This positive cash flow was
partially offset by an increase in costs and estimated earnings in excess of
billings on uncompleted contracts of $283,000. For the three months ended March
31, 2007 the positive cash flow from operations was primarily the result of
a
$499,000 decrease in accounts receivable and a decrease in prepaid expenses
of
$113,000, partially offset by a $300,000 decrease in accounts payable and
accrued expenses and a $59,000 decrease in billings in excess of costs and
estimated earnings on uncompleted contracts.
Net
investing activities used $5,000 and $54,000 of cash in the three months ended
March 31, 2008 and 2007, respectively. For the three months ended March 31,
2008
and 2007, we used cash of $17,000 and $56,000, respectively, for capital
expenditures, primarily at our subsidiary, Metalclad Insulation Corporation.
During the three months ended March 31, 2008 and 2007, cash of $12,000 and
$3,000 was provided by proceeds from sales of assets, respectively.
Cash
used
in financing activities totaled $39,000 for the three months ended March 31,
2008 compared with cash provided by financing activities of $23,000 for the
comparable period in 2007. Proceeds from long-term debt provided $54,000 of
cash
during the three months ended March 31, 2007. Payments on long-term borrowings
used $39,000 and $31,000 of cash in the three months ended March 31, 2008 and
2007, respectively.
The
number of asbestos-related cases which have been initiated naming us (primarily
our subsidiary, Metalclad Insulation Corporation) as a defendant decreased
to
265 in 2004 and to 199 in 2005, but increased in 2006 to 232. The number
decreased to 163 in 2007. At December 31, 2004, 2005, 2006 and 2007, there
were,
respectively, approximately 710, 507, 404 and 222 cases pending. These claims
are currently defended and covered by insurance.
There
were 40 new claims made in the first three months of 2008, compared to 37 in
the
first three months of 2007, and 44 cases resolved in the first three months
of
2008, compared to 66 cases resolved in the first three months of 2007. There
were 218 cases pending at March 31, 2008. These claims are currently defended
and covered by insurance.
The
number of asbestos-related claims made against the Company since 2003, as well
as the number of cases pending at the end of each of those years, has reflected
a general downward trend from 2003 through 2007. We believe that it is probable
that this general trend will continue, although such continuance cannot be
assured. From
2001
and through 2006,
the
annual average indemnity paid on over 2,550 resolved cases has fluctuated
between a low of $14,504 in 2006 and a high of $26,520 in 2001, with an overall
average over that period of approximately $19,131. Since 2001, there has been
no
discernible upward or downward trend in indemnity payments. The indemnity paid
on the 44 cases resolved in the first quarter ended March 31, 2008 averaged
$107,308, as a result of one case in which the plaintiff received a jury award
of $1,659,000 and three other cases settling for approximately $1,000,000 each.
As a further result, we estimate that the average indemnity paid on all claims
resolved in 2008 will increase to over $30,000. We have chosen not to
recalculate the average indemnity based upon the 2008 first-quarter results,
as
we do not anticipate a similar spike in any quarter during the rest of this
year. Accordingly, we intend to continue to use the $19,131 average indemnity
payment in estimating our aggregate asbestos-related personally injury liability
unless we are prompted to alter this number by the next quarter’s results, or
until we are able to take into consideration the results of resolved cases
during the remainder of 2008.
We
believe that the sympathies of juries, the aggressiveness of the plaintiffs’ bar
and the declining base of potential defendants as the result of business
failures, have tended to increase payments on resolved cases. This tendency,
we
believe, has been mitigated by the declining pool of claimants resulting from
death, and the likelihood that the most meritorious claims have been ferreted
out by plaintiffs’ attorneys and that the newer cases being brought are not as
meritorious nor do they have as high a potential for damages as do cases which
were brought earlier. We have no reason to believe, therefore, that the average
future indemnity payments will increase materially in the future.
In
addition, direct defense costs per resolved claim increased from $8,514 in
2003
to $16,700 in 2007. We believe that these defense costs increased as a result
of
a change in legal counsel in 2004, and the more aggressive defense posture
taken
by new legal counsel since that change. We do not believe that the defense
costs
will increase materially in the future, and are projecting those costs to be
approximately $13,500 per claim.
Based
on
the general trend of reducing asbestos-related injury claims made against the
Company over the prior six calendar years, we projected in our Form 10-KSB
filed
with the Securities and Exchange Commission for the year ended December 31,
2006
that there would be 924 asbestos-related injury claims made against the Company
after December 31, 2006. The 924, in addition to the 404 claims existing as
of
December 31, 2006, totaled 1,328 current and future claims. Multiplying the
average indemnity per resolved claim of $19,131, times 1,328, we projected
the
probable future indemnity to be paid on those claims after December 31, 2006
to
be equal to approximately $25 million. In addition, multiplying an estimated
cost of defense per resolved claim of approximately $13,500 times 1,328, we
projected the probable future defense costs to equal approximately $18 million.
Accordingly, our total estimated future asbestos-related liability at December
31, 2006 was $43 million.
As
of
December 31, 2006, we projected that approximately 186 new asbestos-related
claims would be commenced, and approximately 237 cases would be resolved, in
2007, resulting in an estimated 353 cases pending at December 31, 2007. Although
the actual number of claims made in 2007 was 163, and the number of cases
pending as of December 31, 2007 was 222, slightly less than we anticipated,
we
do not believe the differences are significant enough to re-evaluate our
estimate. In addition, our future defense costs and average indemnity per
resolved case could be greater than projected, and such increase could partially
offset any lower projection of liability which would result from such
re-evaluation. Since we projected that an aggregate of 738 new cases would
be
commenced after December 31, 2007, and that 148 of these cases would be
commenced in 2008, we estimated that an aggregate of 590 new cases would be
commenced after December 31, 2008. Accordingly, we have projected the cases
pending and projected to be commenced in the future at December 31, 2008, would
be 897 cases. Multiplying 897 claims times the approximate average indemnity
paid and defense costs incurred per resolved claim from 2002 through 2006 of
$32,600, we estimated our liability for current and future asbestos-related
claims at December 31, 2008 to be approximately $29,000,000. This amounts to
a
$7,000,000 reduction from the $36,000,000 liability we estimated as of December
31, 2007, or a $1,750,000 reduction per quarter in 2008.
We
have
determined that it is probable that we have sufficient insurance to provide
coverage for both current and future projected asbestos-related injury claims.
This determination assumes that the current trend of reducing asbestos-related
injury claims will continue and that the average indemnity and direct legal
costs of each resolved claim will not materially increase. The determination
also assumes that the insurance companies live up to what we believe is their
obligation to continue to cover our exposure with regards to these claims.
Several affiliated insurance companies have brought a declaratory relief action
against our subsidiary, Metalclad, as well as a number of other insurers, to
resolve certain coverage issues. (See Part II, Item 1, “Legal Proceedings -
Asbestos-related Claims”)
We
intend
to re-evaluate our estimate of future liability for asbestos claims at the
end
of each fiscal year, or whenever actual results are materially different from
our estimates, integrating our actual experience in that fiscal year with that
of prior fiscal years since 2002. We estimate that the effects of economic
inflation on either the average indemnity payment or the
projected
direct legal expenses will be approximately equal to a discount rate applied
to
our future liability based upon the time value of money. It is probable that
we
have adequate insurance to cover current and future asbestos-related claims,
although such coverage cannot be assured.
Although
defense costs are included in our insurance coverage, we expended $174,000,
$304,000, $188,000, $215,000 and $296,000 in 2003, 2004, 2005, 2006 and 2007,
respectively, and $65,000 in the three months ended March 31, 2008 to administer
the asbestos claims and defend the ACE Lawsuit discussed below. These amounts
were primarily fees paid to attorneys to monitor the activities of the insurers,
and their selected defense counsel, and to look after our rights under the
various insurance policies.
There
are
numerous insurance carriers which have issued a number of policies to us over
a
period extending from approximately 1967 through approximately 1985 that still
provide coverage for asbestos-related injury claims. After approximately 1985
the policies were issued with provisions which purport to exclude coverage
for
asbestos related claims. The terms of our insurance policies are complex, and
coverage for many types of claims is limited as to the nature of the claim
and
the amount of coverage available. It is clear, however, under California law,
where the substantial majority of the asbestos-related injury claims are
litigated, that all of those policies cover any asbestos-related injury
occurring during the 1967 through 1985 period when these policies were in
force.
We
have
engaged legal counsel to review all of our known insurance policies, and to
provide us with the amount of coverage which such counsel believes to be
probable under those policies for current and future asbestos-related injury
claims against us. Such legal counsel has provided us with its opinion of the
minimum probable insurance coverage available to satisfy asbestos-related injury
claims, which significantly exceeds our estimated $36 million future liability
for such claims as of December 31, 2007. Accordingly, we have included
$34,250,000 and $36,000,000 of such insurance coverage receivable as an asset
on
our March 31, 2008 and December 31, 2007 balance sheets,
respectively.
On
February 23, 2005 ACE Property & Casualty Company ("ACE"), Central National
Insurance Company of Omaha ("Central National") and Industrial Underwriters
Insurance Company ("Industrial"), which are all related entities, filed a
declaratory relief lawsuit (“the ACE Lawsuit”) against Metalclad Insulation
Corporation (“Metalclad”) and a number of Metalclad's other liability insurers,
in the Superior Court of the State of California, County of Los Angeles. ACE,
Central National and Industrial issued umbrella and excess policies to
Metalclad, which has sought and obtained from the plaintiffs both defense and
indemnity under these policies for the asbestos lawsuits brought against
Metalclad during the last four to five years. The ACE Lawsuit seeks declarations
regarding a variety of coverage issues, but is centrally focused on issues
involving whether historical and currently pending asbestos lawsuits brought
against Metalclad are subject to either an "aggregate" limits of liability
or
separate "per occurrence" limits of liability. Whether any particular asbestos
lawsuit is properly classified as being subject to an aggregate limit of
liability depends upon whether or not the suit falls within the "products"
or
"completed operations" hazards found in most of the liability policies issued
to
Metalclad. Resolution of these classification issues will determine if, as
ACE
and Central National allege, their policies are nearing exhaustion of their
aggregate limits and whether or not other Metalclad insurers who previously
asserted they no longer owed any coverage obligations to Metalclad because
of
the claimed exhaustion of their aggregate limits, in fact, owe Metalclad
additional coverage obligations. The ACE Lawsuit also seeks to determine the
effect of the settlement agreement between the Company and Allstate Insurance
Company on the insurance obligations of various other insurers of Metalclad,
and
the effect of the “asbestos exclusion” in the Allstate policy. The ACE Lawsuit
does not seek any monetary recovery from Metalclad. Nonetheless, we anticipate
that we will incur attorneys fees and other associated litigation costs in
defending the lawsuit and any counter claims made against us by any other
insurers, and in prosecuting any claims we may seek to have adjudicated
regarding our insurance coverage. In addition, the ACE Lawsuit may result in
our
incurring costs in connection with obligations we may have to indemnify Allstate
under a settlement agreement. Allstate, in a cross-complaint filed against
Metalclad Insulation Corporation in October, 2005, asked the court to determine
the Company’s obligation to assume and pay for the defense of Allstate in the
ACE Lawsuit under the Company’s indemnification obligations in the settlement
agreement. The Company does not believe that it has any legal obligation to
assume or pay for such defense.
The
Company projects that cash flow generated through the operation of its
subsidiary, Metalclad Insulation Corporation, and the Company’s net cash assets
as of March 31, 2008 will be sufficient to meet the Company’s cash requirements
for at least the next twelve months.
Significant
Accounting Policies
Our
significant accounting policies are described in Note 1 to the consolidated
financial statements included in our annual report for the year ended December
31, 2007. The accounting policies used in preparing our interim 2008
consolidated condensed financial statements are the same as those described
in
our annual report.
Our
critical accounting policies are those both having the most impact to the
reporting of our financial condition and results, and requiring significant
judgments and estimates. Our critical accounting policies include those related
to (a) revenue recognition, (b) investments in unconsolidated affiliates, (c)
allowances for uncollectible notes and accounts receivable, (d) judgments and
estimates used in determining the need for an accrual, and the amount, of our
asbestos liability, and (e) evaluation and estimates of our probable insurance
coverage for asbestos-related claims. Revenue recognition for fixed price
insulation installation and asbestos abatement contracts are accounted for
by
the percentage-of-completion method, wherein costs and estimated earnings are
included in revenues as the work is performed. If a loss on a fixed price
contract is indicated, the entire amount of the estimated loss is accrued when
known. Revenue recognition on time and material contracts is recognized based
upon the amount of work performed. We have made investments in companies which
can still be considered to be in the startup or development stages. We monitor
these investments for impairment considering factors such as the severity and
duration of any decline in fair value, our ability and intent to retain our
investment for a period of time sufficient to allow for a recovery of market
value and based on the financial condition and near-term prospects of these
companies. We make appropriate reductions in carrying values if we determine
an
impairment charge is required. These investments are inherently risky, as the
markets for the technologies or products these companies are developing are
typically in the early stages and may never materialize. Notes and accounts
receivable are reduced by an allowance for amounts that may become uncollectible
in the future. The estimated allowance for uncollectible amounts is based
primarily on our evaluation of the financial condition of the noteholder or
customer. Future changes in the financial condition of a note payee or customer
may require an adjustment to the allowance for uncollectible notes and accounts
receivable. We have estimated the probable amount of future claims related
to
our asbestos liability and the probable amount of insurance coverage related
to
those claims. We offset proceeds received from our insurance carriers resulting
from claims of personal injury allegedly related to asbestos exposure against
the payment issued to the plaintiff. The cash from the insurance company goes
directly to the plaintiff, so we never have access to this cash. We never have
control over any of the funds the insurance company issues to the plaintiff.
Once a claim is settled, payment of the claim is normally made by the insurance
carrier or carriers within 30 to 60 days. Changes in any of the judgments and
estimates could have a material impact on our financial condition and results
of
operations.
Recent
Accounting Pronouncements
See
footnote 9 of the financial statements.
Evaluation
of Disclosure Controls and Procedures
We
have
established disclosure controls and procedures to ensure that material
information relating to the Company is made known to the officers who certify
the financial statements and to other members of senior management and the
Audit
Committee of the Board.
We
conducted an evaluation, under the supervision and with the participation of
our
chief executive officer and chief financial officer of our disclosure controls
and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934). Based on this evaluation our chief
executive officer and chief financial officer have concluded that, as of March
31, 2008, our disclosure controls and procedures are effective.
Changes
in Internal Control Over Financial Reporting
There
have been no changes in our internal controls over financial reporting for
the
three-months ended March 31, 2008 that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.
OTHER
INFORMATION
Asbestos-related
Claims
Prior
to
1975, we were engaged in the sale and installation of asbestos-related
insulation materials, which has resulted in numerous claims of personal injury
allegedly related to asbestos exposure. Many of these claims are now being
brought by the children and close relatives of persons who have died, allegedly
as a result of the direct or indirect exposure to asbestos. To date all of
our
asbestos-related injury claims have been paid and defended by our insurance
carriers.
The
number of asbestos-related cases which have been initiated naming us (primarily
our subsidiary, Metalclad Insulation Corporation) as a defendant decreased
from
265 in 2004 and to 199 in 2005, but increased in 2006 to 232. The number
decreased to 163 in 2007 and was 40 for the three months ended March 31, 2008.
At December 31, 2004, 2005, 2006 and 2007, there were, respectively,
approximately 710, 507, 404 and 222 cases pending. As of March 31, 2008, there
were 218 cases pending. These claims are currently defended and covered by
insurance.
Set
forth
below is a table for the years ended December 31, 2004, 2005, 2006, 2007 and
the
three months ended March 31, 2008, which sets forth for each such period the
approximate number of asbestos-related cases filed, the number of such cases
resolved by dismissal or by trial, the number of such cases resolved by
settlement, the total number of resolved cases, the number of filed cases
pending at the end of such period, the total indemnity paid on all resolved
cases, the average indemnity paid on all settled cases and the average indemnity
paid on all resolved cases:
|
|
2004
|
|
2005
|
|
2006
|
|
2007
|
|
Three
Months
Ended
March
31, 2008
|
|
New
cases filed
|
|
|
265
|
|
|
199
|
|
|
232
|
|
|
163
|
|
|
40
|
|
Defense
judgments and dismissals
|
|
|
311
|
|
|
294
|
(3)
|
|
253
|
|
|
292
|
(3)
|
|
37
|
|
Plaintiff
judgments and Settled cases
|
|
|
97
|
|
|
108
|
|
|
82
|
|
|
53
|
|
|
7
|
|
Total
resolved cases (1)
|
|
|
408
|
|
|
402
|
(3)
|
|
335
|
|
|
345
|
(3)
|
|
44
|
|
Pending
cases (1)
|
|
|
710
|
|
|
507
|
(2,3)
|
|
404
|
|
|
222
|
(3)
|
|
218
|
|
Total
indemnity payments
|
|
$
|
6,366,750
|
|
$
|
8,513,750
|
|
$
|
4,858,750
|
|
$
|
7,974,500
|
|
$
|
4,721,550
|
|
Average
indemnity paid on plaintiff judgments and settled cases
|
|
$
|
65,637
|
|
$
|
78,831
|
|
$
|
59,253
|
|
$
|
150,462
|
|
$
|
674,507
|
|
Average
indemnity paid on all resolved cases
|
|
$
|
15,605
|
|
$
|
21,178
|
(2)
|
$
|
14,504
|
|
$
|
23,114
|
|
$
|
107,301
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Total
resolved cases includes, and the number of pending cases excludes,
cases
which have been settled but which have not been closed for lack of
final
documentation or payment.
|
(2) |
The
average indemnity paid on resolved cases does not include, and the
number
of pending cases includes, a jury award rendered on March 22, 2005
and a
judgment on that award rendered on April 4, 2005, finding Metalclad
Insulation Corporation liable for $1,117,000 in damages, which is
covered
by insurance. The judgment is being appealed by our
insurer.
|
(3) |
Of
the decrease from 710 cases pending at December 31, 2004 to 507 cases
pending at December 31, 2005, were 80 cases which had been previously
counted in error and are included in “Defense judgments and dismissals”
and “Total resolved cases”, so that the actual decrease over the year
ended December 31, 2005 was 123 cases. Included in the decrease from
404
cases pending at December 31, 2006 to 222 cases pending at December
31,
2007, were 53 cases which had been previously counted in error and
are
included in “Defense judgments and dismissals” and “Total resolved cases”,
so that the actual decrease for the year ended December 31, 2007
was 129
cases.
|
The
number of asbestos-related claims made against the Company since 2003, as well
as the number of cases pending at the end of each of those years, has reflected
a general downward trend from 2003 through 2007. We believe that it
is
probable
that this general trend will continue, although such continuance cannot be
assured. From
2001
and through 2006, the annual average indemnity paid on over 2,550 resolved
cases
has fluctuated between a low of $14,504 in 2006 and a high of $26,520 in 2001,
with an overall average over that period of approximately $19,131. Since 2001,
there has been no discernible upward or downward trend in indemnity payments.
The indemnity paid on the 44 cases resolved in the first quarter ended March
31,
2008 averaged $107,308, as a result of one case in which the plaintiff received
a jury award of $1,659,000 and three other cases settling for approximately
$1,000,000 each. As a further result, we estimate that the average indemnity
paid on all claims resolved in 2008 will increase to over $30,000. We have
chosen not to recalculate the average indemnity based upon the 2008
first-quarter results, as we do not anticipate a similar spike in any quarter
during the rest of this year. Accordingly, we intend to continue to use the
$19,131 average indemnity payment in estimating our aggregate asbestos-related
personally injury liability unless we are prompted to alter this number by
the
next quarter’s results, or until we are able to take into consideration the
results of resolved cases during the remainder of 2008.
We
believe that the sympathies of juries, the aggressiveness of the plaintiffs’ bar
and the declining base of potential defendants as the result of business
failures, have tended to increase payments on resolved cases. This tendency,
we
believe, has been mitigated by the declining pool of claimants resulting from
death, and the likelihood that the most meritorious claims have been ferreted
out by plaintiffs’ attorneys and that the newer cases being brought are not as
meritorious nor do they have as high a potential for damages as do cases which
were brought earlier. We have no reason to believe, therefore, that the average
future indemnity payments will increase materially in the future.
In
addition, direct defense costs per resolved claim increased from $8,514 in
2003
to $16,700 in 2007. We believe that these defense costs increased as a result
of
a change in legal counsel in 2004, and the more aggressive defense posture
taken
by new legal counsel since that change. We do not believe that the defense
costs
will increase materially in the future, and are projecting those costs to be
approximately $13,500 per claim.
Based
on
the general trend of reducing asbestos-related injury claims made against the
Company over the prior six calendar years, we projected in our Form 10-KSB
filed
with the Securities and Exchange Commission for the year ended December 31,
2006
that there would be 924 asbestos-related injury claims made against the Company
after December 31, 2006. The 924, in addition to the 404 claims existing as
of
December 31, 2006, totaled 1,328 current and future claims. Multiplying the
average indemnity per resolved claim over the past six years of $19,131, times
1,328, we projected the probable future indemnity to be paid on those claims
after December 31, 2006 to be equal to approximately $25 million. In addition,
multiplying an estimated cost of defense per resolved claim of approximately
$13,500 times 1,328, we projected the probable future defense costs to equal
approximately $18 million. Accordingly, our total estimated future
asbestos-related liability at December 31, 2006 was $43 million.
As
of
December 31, 2006, we projected that approximately 186 new asbestos-related
claims would be commenced, and approximately 237 cases would be resolved, in
2007, resulting in an estimated 353 cases pending at December 31, 2007. Although
the actual number of claims made in 2007 was 163 and the number of cases pending
as of December 31, 2007 was 222, slightly less than we anticipated, we do not
believe the differences are significant enough to re-evaluate our estimate.
In
addition, our future defense costs and average indemnity per resolved case
could
be greater than projected, and such increase could partially offset any lower
projection of liability which would result from such re-evaluation. Since we
projected that an aggregate of 738 new cases would be commenced after December
31, 2007, and that 148 of these cases would be commenced in 2008, we estimated
that an aggregate of 590 new cases would be commenced after December 31, 2008.
Accordingly, we have projected the cases pending and projected to be commenced
in the future at December 31, 2008, would be 897 cases. Multiplying 897 claims
times the approximate average indemnity paid and defense costs incurred per
resolved claim from 2002 through 2006 of $32,600, we estimated our liability
for
current and future asbestos-related claims at December 31, 2008 to be
approximately $29,000,000. This amounts to a $7,000,000 reduction from the
$36,000,000 liability we estimated as of December 31, 2007, or a $1,750,000
reduction per quarter in 2008.
We
have
determined that it is probable that we have sufficient insurance to provide
coverage for both current and future projected asbestos-related injury claims.
This determination assumes that the current trend of reducing asbestos-related
injury claims will continue and that the average indemnity and direct legal
costs of each resolved claim will not materially increase. The determination
also assumes that the insurance companies live up to what we believe is their
obligation to continue to cover our exposure with regards to these claims.
Several affiliated insurance companies have brought a declaratory relief action
against our subsidiary, Metalclad, as well as a number of other insurers, to
resolve certain coverage issues.
We
intend
to re-evaluate our estimate of future liability for asbestos claims at the
end
of each fiscal year, or whenever actual results are materially different from
our estimates, integrating our actual experience in that fiscal year with that
of prior fiscal years since 2002. We estimate that the effects of economic
inflation on either the average indemnity payment or the
projected
direct legal expenses will be approximately equal to a discount rate applied
to
our future liability based upon the time value of money. It is probable that
we
have adequate insurance to cover current and future asbestos-related claims,
although such coverage cannot be assured.
Although
defense costs are included in our insurance coverage, we expended $174,000,
$304,000, $188,000, $215,000 and $296,000 in 2003, 2004, 2005, 2006 and 2007,
respectively, and $65,000 for the three months ended March 31, 2008 to
administer the asbestos claims and defend the ACE Lawsuit discussed below.
These
amounts were primarily fees paid to attorneys to monitor the activities of
the
insurers, and their selected defense counsel, and to look after our rights
under
the various insurance policies.
On
February 23, 2005 ACE Property & Casualty Company ("ACE"), Central National
Insurance Company of Omaha ("Central National") and Industrial Underwriters
Insurance Company ("Industrial"), which are all related entities, filed a
declaratory relief lawsuit (“the ACE Lawsuit”) against Metalclad Insulation
Corporation (“Metalclad”) and a number of Metalclad's other liability insurers,
in the Superior Court of the State of California, County of Los Angeles. ACE,
Central National and Industrial issued umbrella and excess policies to
Metalclad, which has sought and obtained from the plaintiffs both defense and
indemnity under these policies for the asbestos lawsuits brought against
Metalclad during the last four to five years. The ACE Lawsuit seeks declarations
regarding a variety of coverage issues, but is centrally focused on issues
involving whether historical and currently pending asbestos lawsuits brought
against Metalclad are subject to either an "aggregate" limits of liability
or
separate "per occurrence" limits of liability. Whether any particular asbestos
lawsuit is properly classified as being subject to an aggregate limit of
liability depends upon whether or not the suit falls within the "products"
or
"completed operations" hazards found in most of the liability policies issued
to
Metalclad. Resolution of these classification issues will determine if, as
ACE
and Central National allege, their policies are nearing exhaustion of their
aggregate limits and whether or not other Metalclad insurers who previously
asserted they no longer owed any coverage obligations to Metalclad because
of
the claimed exhaustion of their aggregate limits, in fact, owe Metalclad
additional coverage obligations. The ACE Lawsuit also seeks to determine the
effect of the settlement agreement between the Company and Allstate Insurance
Company on the insurance obligations of various other insurers of Metalclad,
and
the effect of the “asbestos exclusion” in the Allstate policy. The ACE Lawsuit
does not seek any monetary recovery from Metalclad. Nonetheless, we anticipate
that we will incur attorneys fees and other associated litigation costs in
defending the lawsuit and any counter claims made against us by any other
insurers, and in prosecuting any claims we may seek to have adjudicated
regarding our insurance coverage. In addition, the ACE Lawsuit may result in
our
incurring costs in connection with obligations we may have to indemnify Allstate
under a settlement agreement. Allstate, in a cross-complaint filed against
Metalclad Insulation Corporation in October, 2005, asked the court to determine
the Company’s obligation to assume and pay for the defense of Allstate in the
ACE Lawsuit under the Company’s indemnification obligations in the settlement
agreement. The Company does not believe that it has any legal obligation to
assume or pay for such defense.
In
2003
and 2004 the Judiciary Committee of the United States Senate considered
legislation to create a privately funded, publicly administered fund to provide
the necessary resources for an asbestos injury claims resolution program, and
is
commonly referred to as the “FAIR” Act. In 2005, a draft of the “FAIR” Act was
approved by the Judiciary Committee, but the bill was rejected by the full
Senate in February 2006, when a cloture motion on the bill was withdrawn. An
amended version of the 2006 “FAIR” Act (S 3274) was introduced in the Senate in
May 2006, but has not been scheduled for a vote. A similar bill was introduced
in the House (HR 1360) in March 2005, but was referred to a subcommittee in
May
2005. The latest draft of the “FAIR” Act calls for the fund to be funded
partially by asbestos defendant companies, of which the Company is one, and
partially by insurance companies. The bill could be voted on by the Senate
or
the House at any time in the future. The impact, if any, the “FAIR” Act will
have on us if passed cannot be determined at this time although the latest
draft
of the legislation did not appear favorable to us.
Claim
Against Former Employee, Etc.
In
October 1999, we completed the sale of our operating businesses and development
project located in Aguascalientes, Mexico. That sale specifically excluded
those
Mexican assets involved in the Company’s NAFTA claim which was settled in 2001.
Under the terms of the sale we received an initial cash payment of $125,000
and
recorded a receivable for $779,000, which has been fully reserved. On November
13, 2000, the Company filed a complaint in the Superior Court of California
against a former employee, the U.S. parent of the buyer and its representative
for breach of contract, fraud, collusion and other causes of action in
connection with this sale seeking damages in the form of a monetary award.
An
arbitration hearing was held in September, 2002 in Mexico City, as requested
by
one of the defendants. This arbitration hearing was solely to determine the
validity of the assignment of the purchase and sale agreement by the buyer
to a
company formed by the former employee defendant. The Superior Court action
against the U.S. parent was stayed pending the Mexican arbitration. On April
8,
2003, the arbitrator ruled that the assignment was inexistent, due to the
absence of our consent. In June 2003, the
Court
of
Appeal for the State of California ruled that the U.S.
parent was also entitled to compel a Mexican arbitration of the claims raised
in
our complaint. We are now prepared to pursue our claim in an arbitration
proceeding for the aforementioned damages. No assurances can be given on the
outcome.
In
a
related action, a default was entered against us in December, 2002, in favor
of
the same former employee referred to in the foregoing paragraph by the Mexican
Federal Labor Arbitration Board, for an unspecified amount. The former employee
was seeking in excess of $9,000,000 in damages as a result of his termination
as
an employee. The default was obtained without the proper notice being given
to
us, and was set aside in the quarter ended June 30, 2003. The Mexican Federal
Labor Arbitration Board rendered a recommendation on December 13, 2004, to
the
effect that the former employee was entitled to an award of $350,000 from Entrx
in connection with the termination of his employment. The award is in the form
of a recommendation which has been affirmed by the Mexican Federal Court, but
is
only exercisable against assets of the Company located in Mexico. The Company
has no material assets in Mexico. The award does not represent a collectible
judgment against the Company in the United States. Since the Company has no
material assets in Mexico, the likelihood of any obligation to satisfy this
award is remote, and we therefore believe that there is no potential liability
to the Company which needs to be recorded in our financial statements. The
Company intends to continue to pursue its claims against the same employee
for
breach of contract, fraud, collusion and other causes of action in connection
with the 1999 sale of one of the Company’s operating businesses in
Mexico.
On
May
31, 2006, we entered into a Settlement Agreement with Ventana Global
Environmental Organizational Partnership, L.P. and North America Environmental
Fund, L.P. (collectively referred to as “Ventana”) whereby Ventana agreed to pay
Entrx Corporation $1,250,000 in exchange for the dismissal with prejudice by
Entrx Corporation of the law suit (the “Ventana Action”) filed by Entrx
Corporation against Ventana and others in Orange County, California Superior
Court in November 2000. Entrx Corporation and Ventana also entered into a mutual
release of all claims each may have had against the other. In addition, Entrx
Corporation released Carlos Alberto de Rivas Oest and Geologic de Mexico S.A.
de
C.V., which were parties related to Ventana, and against whom Entrx Corporation
had claims pending in Mexico. The Settlement Agreement does not limit claims
that Entrx had or currently has against Javier Guerra Cisneros and Promotora
Industrial Galeana, S.A. de C.V., which Entrx Corporation continues to pursue
in
Mexico. Javier Guerra Cisneros and Promotora Industrial Galeana, S.A. de C.V.
were involved with the transactions which were the subject of the Ventana
Action. Entrx Corporation received approximately $925,000 net after payment
of
legal fees and expenses associated with the Ventana Action and the Settlement
Agreement.
Since
the
May 2006 Settlement Agreement, the remaining action against Javier Guerra
Cisneros and Promotora Industrial Galeana, S.A. de C.V has experienced repeated
and extended delays in the State Court in Mexico City. In the fourth quarter
of
2007, the Company filed an amparo
(injunction) application
with the Mexican federal court in Mexico City, requesting that the State Court
take affirmative action in the Company's pending case. That amparo
was
denied during the first quarter of 2008 and an appeal has been presented to
the
federal appellate court. A ruling on the appeal is expected within the
next 90 days.
At
a
Special Meeting of Shareholders held on January 28, 2008, the following persons
were elected, by the votes indicated, as the members of the Board of Directors
of the Company, each to serve until the next annual meeting of the shareholders
or the election of a successor:
|
|
Number
of Shares
|
|
|
|
For
|
|
Against
|
|
Abstentions
|
|
Broker
Non-votes
|
|
Peter
L. Hauser
|
|
|
6,592,121
|
|
|
147,620
|
|
|
-
|
|
|
-
|
|
Joseph
M. Caldwell
|
|
|
6,451,927
|
|
|
287,814
|
|
|
-
|
|
|
-
|
|
David
E. Cleveland
|
|
|
6,592,125
|
|
|
147,616
|
|
|
-
|
|
|
-
|
|
E.
Thomas Welch
|
|
|
6,591,922
|
|
|
147,819
|
|
|
-
|
|
|
-
|
|
Also
voted on at the Special Meeting of Shareholders held on January 28, 2008, was
a
proposed amendment to the Company’s certificate of Incorporation which would
effect a 1-for-500 reverse split of the Company’s outstanding
common
stock,
followed by a 500-for-1 stock split, which would cash out shareholders owning
less than 500 shares. The vote totals for the proposed amendment were as
follows:
Number
of Shares
|
|
For
|
|
Against
|
|
Abstentions
|
|
Broker
Non-votes
|
|
2,288,781
|
|
|
800,106
|
|
|
3,914
|
|
|
3,646,940
|
|
Since
adoption of the motion required the affirmative vote of a majority of the
outstanding shares, or 3,808,734 shares, the motion was not
adopted.
Exhibits
|
31.1 |
Rule
13a-14(a) Certification of Chief Executive
Officer.
|
|
31.2 |
Rule
13a-14(a) Certification of Chief Financial
Officer.
|
|
32 |
Section
1350 Certification.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
ENTRX
CORPORATION
Date:
May
9, 2008
Peter
L.
Hauser
Chief
Executive Officer
Date:
May
9, 2008
Brian
D.
Niebur
Chief
Financial Officer
(Principal
Accounting Officer)